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Abstract
The accumulation of ‘senescent’ cells has long been proposed to act as an
ageing mechanism. These cells display a radically altered transcriptome and
degenerative phenotype compared with their growing counterparts.
Tremendous progress has been made in recent years both in understanding
the molecular mechanisms controlling entry into the senescent state and in the
direct demonstration that senescent cells act as causal agents of mammalian
ageing. The challenges now are to gain a better understanding of how the
senescent cell phenotype varies between different individuals and tissues,
discover how senescence predisposes to organismal frailty, and develop
mechanisms by which the deleterious effects of senescent cells can be
ameliorated.
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What is cell senescence?
Historically, ‘senescent’ cells are the living, but permanently non-
dividing, forms of cells that are normally capable of replication 
within mammalian tissues. Thus, it is possible to have both growing 
and senescent forms of fibroblasts, keratinocytes, astrocytes, myob-
lasts, endothelial cells, or vascular smooth muscle cells but not 
mature neurones, skeletal muscle fibres, or lens fibre cells. Describ-
ing these latter cells as ‘senescent’ is usually, but not always, an 
unfortunate homonym that indicates that the writer is referring to 
material taken from an aged donor (q.v.).
The senescent state is distinct from necrosis, apoptosis, and the 
multiple overlapping molecular states of transient growth arrest col-
lectively called quiescence1, although linkages to these appear to 
be mediated through the mechanistic target of rapamycin (mTOR) 
axis2. In biological systems where the two processes can be readily 
separated, principally keratinocytes, senescence can also be shown 
to be distinct from terminal differentiation3. Senescence limits the 
capacity for expansion of clones of cells and thus prevents them 
from accumulating or expanding procarcinogenic mutations, thus 
acting as an in vivo barrier to carcinogenesis. It is thereby effectively 
a process-level form of the evolutionary mechanism of action termed 
‘antagonistic pleiotropy’. Perhaps unsurprisingly, evidence is grad-
ually accumulating that the short-term presence of senescent cells is 
beneficial in a range of normal physiological processes, including 
wound healing and placental development (reviewed in 4).
How does cell senescence work?
Senescence was famously first reported by Hayflick and Moorhead 
as a phenomenon limiting the capacity of populations of normal 
human lung fibroblasts to continue to expand in vitro5. Cell senes-
cence has been overwhelmingly studied by using fibroblasts ever 
since, and this is perhaps an example of experimental tractability 
trouncing physiological relevance. These classic systems provided 
most of the contextual data and assays for senescence that were 
subsequently deployed in other cell types. This is perhaps best illus-
trated by the methods used to detect senescent cells. Early studies 
simply used lack of growth under conditions that would normally 
allow mitosis to occur. By the early 1970s and through the 1980s, 
two different major techniques were usually employed. The first, 
following largely from the work of Cristofalo, used label exclusion 
as the primary measure of the senescent state. This involved label-
ling fibroblast populations for periods significantly in excess of the 
cell cycle time (typically 72 hours for fibroblasts with a cell cycle 
time of about 24 hours) with 3H thymidine or later bromodeoxyu-
ridine. A lack of label incorporation definitively indicated a senes-
cent cell6. In parallel, Hayflick, Smith, Whitney, and their associates 
used the isolation of individual cells and the measurement of their 
clonal lifespans to probe the senescent state and yielded impres-
sive data concerning the nature of the molecular machinery7,8. This 
non-invasive technique for studying interclonal variation in repli-
cative capacity could fairly be said to have reached its zenith in 
the work of Shall and colleagues on human and rodent mortal cell 
populations9.
Problematically, these simple techniques did not typically allow 
researchers to distinguish between senescent and quiescent cells 
in intact tissue (Wolfe was able to combine them in studies on 
senescence in vivo to show reduced accumulation of senescent cells 
with calorie restriction10 in the rodent lens; however, this was a tech-
nical tour de force). This lack of a utile marker for senescent cells 
in tissue hampered, and to some extent continues to hamper, the 
routine detection, quantitation, and localisation of senescent cells 
in vivo. The development of the senescence-associated β galactosi-
dase assay by Dimri et al.11 thus represented a significant improve-
ment. Based on a combination of serendipity and classic catalytic 
histochemistry, it relies on the fact that many senescent cell types 
have enlarged secondary lysosomes and thus elevated β galactosi-
dase (in fact, variations of the assay also work using substrates for 
dipeptidyl peptidase-2, dipeptidyl peptidase-4, and aminopeptidase 
m; Faragher, unpublished observations). Because catalytic histo-
chemical techniques were originally developed to produce quanti-
tative data on enzyme activity in tissues (significantly predating the 
routine use of immunocytochemistry), the senescence-associated 
β galactosidase assay was readily applicable to fresh tissue sec-
tions. Interestingly, alternative techniques based on other aspects 
of the classic senescent fibroblast phenotype such as the auto- 
fluorescence associated with the accumulation of lipofuscin are 
being developed12,13 and clearly hold considerable promise pro-
vided that users do not expect too much (‘too much’ in this instance 
is shorthand for “a single, perfect, rapid, easy-to-use, definitive 
biomarker for senescent cells that works in each and every cell type 
from all species under every conceivable set of conditions”).
In serially passaged cultures of human fibroblasts, senescence pri-
marily occurs because progressive telomere shortening triggers 
permanent cell cycle arrest through the tumour suppressor gene 
p53 and the cyclin-dependent kinase inhibitor p2114. These short 
telomeres arise as a result both of the classic ‘end-replication prob-
lem’ associated with the replication of linear chromosomes and 
of the relatively low efficiency of DNA repair at telomeres15. This 
discovery allowed the use of telomere dysfunction-induced foci 
(essentially short telomeres in combination with proteins, including 
γH2AX and 53BP1) as markers of senescence. This technique has 
been used to demonstrate the presence of senescent cells in pri-
mate skin and their accumulation with age but remains technically 
challenging16,17.
Telomere-dependent senescence is the primary mode of entry into 
the senescent state in vitro for many human cell types, including 
fibroblasts, retinal pigmented epithelial cells, endothelial cells, and 
urothelial cells14,18–20. However, alternative pathways exist based on 
the action of the cyclin-dependent kinase inhibitor p16 (a selective 
inhibitor of cyclin D-CDK4/6 kinase pairs)18 or as a direct result of 
the activation of p53 independent of telomere shortening19. Rodent 
fibroblasts in vitro enter senescence through a pathway akin to 
this latter mechanism, which requires the activity of the p19 (p14 
in human) ARF tumour suppressor protein (the alternate reading 
frame of the p16INK4 locus) and p16 itself21,22. Thus, the detection 
of p16 at the message or protein level can form a useful marker for 
the presence of senescent cells, although, as with the majority of 
histochemical techniques, the use of a single marker does not allow 
definitive assignment of the senescent state23.
This basic network can be linked to a broad series of cellular stres-
sors. These include, but are not limited to, oncogene activation, 
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elevated levels of reactive oxygen species (stress-induced prema-
ture senescence), stress signalling in the endoplasmic reticulum (ER 
stress), glyoxal-induced senescence (metabolic stress), and trans-
forming growth factor beta-induced cellular senescence (reviewed 
in 4). Thus, a wide range of stimuli have the potential to give rise 
to senescent cells in different tissues and different individuals. A 
complex variety of molecular mechanisms act to maintain senes-
cence, including secreted cytokines (reviewed in 24) and altered 
mitochondrial function25.
At least two of the three known primary senescence pathways seen 
in human cells are probably present in mice in vivo. Ironically, the 
only pathway that seems definitively absent in wild-type mice (as 
opposed to telomerase-null animals) is the telomere length-dependent 
senescence mechanism regularly observed in human cells22,26–28. 
Rather, this appears to be present only in large, long-lived species 
as an additional tumour suppression mechanism. This trend can be 
observed within the order Rodentia, in which house mice and rats 
have long telomeres and active telomerase whereas fibroblasts from 
the much larger beavers, porcupines, and capybaras have telomeres 
much closer to human length and lack telomerase activity27.
However, this does not mean that telomeric effects cannot play 
causal roles in cellular senescence in laboratory rodents. Although 
telomerase knockout mice are essentially aphenotypic for several 
generations because of their long telomeres, Passos and colleagues 
have shown that damage at the telomere is difficult to repair, result-
ing in telomerase-positive cells entering a senescent state when they 
are dosed with gamma radiation29. Telomere-associated damage 
foci similar to those seen in vitro can be observed in vivo as labora-
tory mice age, suggesting that this mechanism generates senescent 
cells under normal conditions.
Cell senescence causes ageing: from wishful 
thinking to case closed?
From its initial discovery, it was postulated that senescence, on 
some level, was linked with organismal ageing. Modern forms of 
this hypothesis propose that senescent cells are produced gradu-
ally throughout life. These then begin to accumulate in mitotic 
tissues and act as causal agents of the ageing process through the 
disruption of tissue function. This conceptual model carries three 
underlying assumptions: firstly that senescent cells are present 
in vivo, secondly that they accumulate with age, and finally that an 
accumulation of senescent cells can have a negative impact. Each is 
worthy of examination.
A steady production of senescent cells is quite plausible if the kinet-
ics whereby populations of normal cells become senescent in vitro 
are assumed to be similar in vivo. Many early reports evaluated 
findings with the mistaken underlying assumption that cell cultures 
become senescent because all of the cells divide synchronously for 
a fixed number of times and then stop. In fact, it has been known 
since the early 1970s that each time a cell goes through the cell 
cycle (i) it has a finite chance of entering the senescent state and 
(ii) this chance increases with each subsequent division6–9,30. Thus, 
senescent cells appear early on if a cell population is required to 
divide. Indirect demonstrations that senescent cells occur in vivo, 
accumulate with ageing, and do so at reduced rates in organisms 
where ageing is slowed (for example, by dietary restriction) were 
occasionally published from the 1970s onwards10,11,31.
However, they were technically difficult to perform and correspond-
ingly hard to interpret.
The presence of senescent cells would be less of a physiologi-
cal handicap if they behaved in ways indistinguishable from their 
growth-competent counterparts. Unfortunately, senescence triggers 
changes in gene expression on (roughly) the same scale as differ-
entiation from one cell type into another32,33. A central component 
of this shift is the secretion of biologically active proteins (for 
example, growth factors, proteases, and cytokines) that have potent 
autocrine and paracrine activities, a process termed the senescence-
associated secretory phenotype (SASP)34,35. This results in cells 
that overproduce a wide variety of pro-inflammatory cytokines, 
typically through the induction of nuclear factor kappa B (NF-
κB)36 and matrix-degrading proteins such as collagenase37. Other 
radical phenotypic changes, such as calcification, have also been 
shown to occur in some cell types with the onset of replicative 
senescence32,38.
The individual components of the SASP vary from tissue to tissue 
and, within a given cell type, can differ depending upon the stimu-
lus used to induce senescence (for example, in fibroblasts rendered 
senescent by oncogene activation compared with telomere attrition 
or mitochondrial dysfunction)39–41. Such studies demonstrated that 
senescent cells could, at least potentially, produce significant and 
diverse degenerative pathology.
However, the observation that something can produce pathology 
does not mean that it must produce pathology, and a historic weak-
ness of the cell senescence literature was that the in vivo studies 
essential to testing the causal relationship between ageing and cellu-
lar senescence (induced by any mechanism) were lacking. However, 
the production of transgenic mouse models in which it was possible 
to eliminate senescent cells has finally made such tests experimen-
tally feasible. Initial studies42 demonstrated first that senescent cells 
appeared to play a causal role in a variety of age-associated pathol-
ogies in the BubR1 mutant mouse and subsequently that either 
life-long removal of senescent cells or their clearance late in life sig-
nificantly attenuated the development of such pathologies in these 
progeroid animals43. This clearly demonstrated that senescent cells 
can have significant, deleterious effects in vivo. Interestingly, the 
removal of senescent cells in this system was not associated with 
increased lifespan (an observation that demonstrated that it is possi-
ble to achieve classic ‘compression of morbidity’ by deleting senes-
cent cells). However, on more conventional genetic backgrounds, 
attenuated age-related organ deterioration was accompanied by 
increases in lifespan of the order of 25%44. A justifiable claim can 
be made to consider these studies ‘landmarks’ in the field in that (i) 
they demonstrate a causal relationship between senescent cells and 
‘ageing’ and (ii) the same mechanism can cause changes associated 
with ‘ageing’ as well as those associated with ‘age-related disease’. 
These results have unusually profound philosophical implications 
for a scientific paper and challenge a fundamental ontological dis-
tinction that has been drawn for almost two thousand years between 
‘natural’ ageing and ‘unnatural’ disease45.
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The interaction between senescence and the age-related loss or 
functional alteration of terminally differentiated post-mitotic cell 
populations such as skeletal muscle fibres or neurons has been rela-
tively little studied. Such interactions could occur in at least two 
distinct ways: (i) paracrine effects on neurons or muscle fibres by 
senescent cells from adjacent mitotic compartments (for example, 
muscle satellite cells, fibroblasts, endothelial cells, or adipocytes) 
and (ii) cell-intrinsic changes in phenotype in muscle or neurons 
resulting from activation of the same pathways that give senes-
cent cells their distinctive phenotype (for example, the activation 
of NF-κB). Given that approximately 30 to 40% of the human 
body is muscle, either of these could be physiologically highly 
significant46.
In the first case, there is ample potential for senescent cells to trig-
ger inflammatory responses in neuromuscular tissue, which then 
can be compounded by muscle and neuronal cells, leading to more 
widespread tissue dysfunction. In the second, it is already known 
that DNA damage in mature neurons in vivo induces a p21waf- 
mediated elevation in interleukin-6 production, conversion of 
euchromatin into heterochromatin, and elevated levels of lysosomal 
enzyme activity (analogous to that seen in senescent fibroblasts). 
Such damaged neurons accumulate with advancing age in vivo and 
that accumulation can be partially rescued by dietary restriction47. 
The researchers who reported these observations termed the neuro-
nal phenotype a ‘senescence-like state’, which is perfectly accurate 
but potentially confusing for those with only a cursory interest in 
the field. A suitably colourless neologism (perhaps geroversion, 
gerotype, or senoversion) for such phenotypic changes occurring in 
cell types that are already post-mitotic would seem to be called for, 
as would further investigation of their effects on tissue function.
Cell senescence: where next?
Although senescent cells play an important role in tumour sup-
pression and some unsuspected aspects of normal physiology48–50, 
they are central players both in age-related mortality and in vari-
ous forms of morbidity (for example, as causal agents of adverse 
reactions to chemotherapy). However, data on their phenotype and 
behaviour fall far short of what is required if therapeutic progress 
is to be made in a reasonable timescale. For example, systematic 
studies on the frequency and distribution of senescent cells in 
human tissue analogous to those carried out on baboon skin remain 
to be performed (as opposed to proxy markers such as telomere 
length, which have been covered in more depth51). The result is a 
literature on in vivo senescence in human tissues that is currently 
fragmentary and frustratingly difficult to interpret. Even such an 
apparently straightforward question such as whether the frequency 
of senescent cells is elevated in the skin of patients with accelerated 
ageing disorders such as Werner’s syndrome remains unknown. 
This is not because those in the field do not recognise the utility of 
such work; rather, it is that studies of this type are considered—in 
the words of one anonymous but unsympathetic referee—“boring 
descriptive work”. Similar issues of problem choice have occurred 
in other branches of ageing research at different times (for exam-
ple, the merits of studying the pathology of ageing in Caenorhab-
ditis elegans relative to the identification of new mutants affecting 
lifespan52). Thus, linkages to the fraction of senescent cells required 
to produce degenerative effects in any given human tissue remain 
speculative and largely based on in vitro data; a figure of about 10% 
of the total cell population would seem to be sufficient53,54.
Whether an enhanced emphasis on basic human studies is a useful 
parallel-track approach to the pioneering work now taking place in 
rodent models or an essential next step is a matter of perspective. 
Many fundamental mechanisms of ageing are conserved between 
species (such as the insulin–insulin-like growth factor 1 axis), 
but there are often important species-specific differences. Those 
inclined to stress the cross-species similarities will be inclined to 
deprioritise human studies and vice versa.
Regardless of the species of origin, the extent of variation in the 
phenotype of senescent cells derived from the same tissue in dif-
ferent individuals is not well characterised. Whilst there are clearly 
commonalities to aspects of the senescent phenotype such as the 
SASP34,35,55, it would be surprising if important intra-individual 
variation did not exist within the general population as well as ‘out-
liers’ (for example, centenarians and those with accelerated ageing 
diseases such as Werner’s syndrome56). Although data on differen-
tial SASP profiles in response to a senescence stimulus are begin-
ning to enter the literature, they remain fragmentary concerning the 
senescent cell phenotype in different tissues.
Despite these gaps, progress is being made towards the develop-
ment of ‘senolytic’ drugs that can destroy senescent cells—with the 
goal of duplicating the effects of the transgenic mouse models first 
in normal animals and eventually in human patients. Initial results 
seem promising; for example, the BCl2 inhibitor navitoclax was 
shown to be senolytic in some types of senescent cells (for example, 
rodent fibroblasts and human endothelia) but not others (for exam-
ple, human primary preadipocytes)57. Recently, navitoclax was 
shown to provide therapeutic benefit in rodent models of athero-
sclerosis, mimicking the effects of senescent cell deletion models 
and reducing the size, number, and overall burden of atherosclerotic 
plaques58.
Dual treatment with the senolytic compounds dasatinib and querce-
tin mimics the results seen in transgenic mouse senescence clearance 
models and improves both vasomotor function and vascular stiffness 
in aged and atherosclerotic mice, although the mechanistic spec-
trum of action of these compounds is broad and caution needs to be 
applied in ascribing the improvements in health status seen in senoly-
sis alone59. Quercetin also inhibits matrix metalloproteinase activity, 
another canonical senescence marker60. This demonstrates the poten-
tial of an alternative route to dealing with the degenerative effects 
of senescent cells, blocking their effects rather than killing them, 
although improved pharmacological profiles are required before 
such treatments can progress further. The polyphenolic resveratrol 
also inhibits matrix-degrading enzymes and shows significant anti-
inflammatory effects60–63. Though apparently not senolytic, resvera-
trol blocks both the SASP in fibroblasts and the pro-calcificatory 
phenotype in vascular smooth muscle cells61,63,64. In addition, it has 
a range of beneficial effects on post-mitotic cell types, improving 
muscle mass, strength, and fatigue in rodent models65–67 and show-
ing beneficial effects in a range of neuronal models68.
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Some of resveratrol’s beneficial effects appear to occur through the 
suppression of NF-κB activation62, suggesting that blockade of this 
pathway may be of general benefit in treating senescence. The poten-
tial utility of selective NF-κB inhibition was recently demonstrated 
in XPF-ERCC1 mutant mice, which show a wide range of prog-
eroid features. In this model, either genetic depletion of one allele 
of the p65 subunit of NF-κB or treatment with a peptide inhibitor 
of the NF-κB activator IKK (8K-NBD, consisting of the NEMO-
binding domain, fused to an 8K protein transduction domain) sig-
nificantly delayed the onset of symptoms69. Such studies could be 
usefully combined with other models of progeroid pathology, such 
as BubR1. Drugs already in clinical use, such as rapamycin and 
metformin, also modulate the SASP, suggesting that at least some 
of their beneficial effects are mediated via this route70,71.
Many aspects of the biology of senescent cells and the relationship 
of that biology to the aged phenotype remain to be uncovered. For 
example, RNA splicing factor expression alters profoundly during 
the ageing of both humans and rodents. This has the potential to 
compromise the ability of an aged tissue to produce a full spectrum 
of proteins in response to a physiological challenge (such as cold or 
heat stress). Changes to alternative splicing are also associated with 
replicative senescence in vitro, suggesting that this shift in the intact 
organism either results from the accumulation of senescent cells or 
is a parallel process affecting both senescent cells and those that 
have been called on to cycle repeatedly72. We have extensive data 
showing that resveralogues reverse these changes in splicing factor 
expression in vitro and rescue multiple features of senescence inde-
pendently of cell cycle traverse, SIRT1 activation, or SASP modu-
lation. Understanding the mechanism of action of these compounds 
in greater detail will allow the development of small-molecule 
anti-degenerative treatments and provide another novel means of 
improving healthspan, the central goal of modern geroscience.
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